Answers are grounded in this paper and cite their sources.
The urgent deployment of novel vaccines during a global pandemic inevitably comes with limitations in initial vaccine supply, which requires prioritisation of population groups. Hassan-Smith and colleagues recently argued that it is essential to develop a plan “that takes the growing body of evidence on the effect of comorbidities, occupational, and socioeconomic factors on COVID-19 severity into account” [1].
No takes yet. Share an insight, caveat, or question.
Campos-Matos et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: